Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

Left unmanaged, this diabetes-related complication can lead to vision changes. Implementing the right strategies can help you protect your eyesight. When high blood sugar levels related to diabetes ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. UBX1325 met safety and efficacy endpoints at 24 weeks in ...

A recent study published in the journal Nature Medicine showed that targeting senescent cells in the retina can be a lasting disease-modifying treatment for diabetic macular edema (DME). The retina is ...

Please provide your email address to receive an email when new articles are posted on . Lamivudine improved visual acuity in patients with center-involved diabetic macular edema. Researchers said the ...

Diabetic macular edema (DME) occurs when fluid accumulates behind the macula, the part of your retina that processes central vision. DME can occur at any stage of diabetic retinopathy (DR). However, ...

Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach. What are the ...

Sunir J. Garg, MD, shares his recent experience at the American Academy of Ophthalmology Annual Meeting in San Francisco and highlights two key takeaways. First, Dr Garg explores the ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...

FDA has announced it has approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, according to a news release. DME is a sight-threatening eye disease that occurs in ...

LONDON--(BUSINESS WIRE)--The global diabetic macular edema treatment market 2018-2022 is expected to post a CAGR of more than 1% during the forecast period, according to the latest market research ...